BioLife Solutions, Inc. — 2014 Form 10-K
Business context and reporting period. Annual report for the fiscal year ended December 31, 2014, filed March 12, 2015. BioLife develops and sells biopreservation media, custom manufacturing services, and temperature-controlled shipping products for cell, tissue, and organ applications. This filing reports full-year results, not standalone fourth-quarter results.
Key financial results
| Metric | 2014 | 2013 |
|---|---|---|
| Total revenue | $6.19 million | $8.95 million |
| Gross profit / margin | $3.04 million / 49.0% | $3.76 million / 42.0% |
| Operating expenses | $6.17 million | $4.05 million |
| Operating loss | $3.14 million | $0.29 million |
| Net loss attributable to BioLife | $3.22 million | $1.08 million |
| Cash used in operations | $3.16 million | Cash provided: $0.15 million |
| Cash and cash equivalents | $2.54 million | $0.16 million |
| Short-term investments | $7.40 million | None reported |
At year-end, cash, cash equivalents, and short-term investments totaled $9.94 million. Current assets were $12.17 million versus current liabilities of $1.26 million. Total liabilities were $2.14 million; the $14.3 million of related-party debt and accrued interest was converted to equity in March 2014. The company reported no off-balance-sheet arrangements and no cash income-tax payment or provision.
Material changes versus 2013
- Revenue fell 31%, principally because contract-manufacturing revenue declined to $1.28 million from $4.42 million after the major customer contract ended in May 2014. Core product sales increased 25% to $4.91 million.
- Gross margin rose to 49.0% from 42.0%, reflecting the higher proportion of core product sales. The filing says 2013 margin would have been 37.8% excluding $0.61 million of licensing revenue with no associated cost.
- Operating expenses increased 52% to $6.17 million, with higher research and development, sales and marketing, and general and administrative costs. The company’s net loss attributable to BioLife nearly tripled.
- BioLife raised $13.60 million net in a March public offering and converted approximately $14.3 million of related-party debt and accrued interest into equity, materially improving the balance sheet but increasing shares and potential dilution.
Outlook, commentary, and risks
For 2015, management targeted 20%–30% growth in proprietary product revenue and gross margins of 50%–60%. It expected cash use and operating loss to increase by as much as 30%, mainly from sales, marketing, and biologistex investment. Management said available liquidity should meet needs for the foreseeable future; results remain dependent on adoption, customer clinical and commercial success, and competition.
- BioLife formed biologistex, a 20-year joint venture with SAVSU; BioLife owns 52%. The venture’s smart-container and cloud-monitoring offering was expected to launch commercially in the first half of 2015. BioLife committed a $2.4 million capital contribution, a $1 million participation fee payable subject to performance requirements, and management/services support; biologistex committed to approximately $2.6 million in minimum container purchases from SAVSU over 24 months. The filing states the $2.4 million contribution remained outstanding at year-end.
- Customer concentration remains important: one contract-manufacturing customer represented 18% of 2014 revenue, down from 49% in 2013; another customer represented 11% in 2014. Management warns that demand from regenerative-medicine customers can be uneven and may depend on regulatory approvals and commercialization of their therapies.
- Other risks include recurring losses and possible need for further capital, reliance on outside suppliers, competition from larger companies, joint-venture execution and governance risks, and intellectual-property and manufacturing risks. Two stockholders collectively owned approximately 50.5% of shares at year-end.
- The company reported no material legal proceedings. Management concluded disclosure controls and internal control over financial reporting were effective; the auditor did not attest to internal control effectiveness.
Investor verification points
- Confirm subsequent results against the 2015 revenue-growth and gross-margin targets, and track operating losses and cash use.
- Assess whether core product growth can offset the loss of the terminated contract-manufacturing customer and reduce customer concentration.
- Verify biologistex launch progress, sales milestones, the remaining capital contribution, minimum purchase obligations, and any intercompany funding needs.
- Review liquidity, investment maturities, and any additional financing needs; also account for the 7.43 million outstanding warrants and other potential share issuance when assessing dilution.
- Monitor customer regulatory approvals and commercial launches that could drive future demand for BioLife products.